tolfenamic-acid has been researched along with Fever* in 3 studies
1 trial(s) available for tolfenamic-acid and Fever
Article | Year |
---|---|
Use of tolfenamic acid in febrile children with and without glucose-6-phosphate dehydrogenase deficiency.
The purpose of this study was to evaluate the antipyretic action of tolfenamic acid, as well as its possible adverse reactions, especially in children with severe or partial form of glucose-6-phosphate dehydrogenase (G6PD) deficiency. In the study 55 febrile children were included, whose mean age was +/- SD 3.5 +/- 3.3 years, range 0.5-15. Ten of them had severe or partial form of G6PD deficiency. Fifty-three of the patients responded with a decrease of temperature which lasted at least 6 hours, though in 2 of them the temperature decrease lasted less than 6 hours. The tolerance of the drug was good and no side-effects were noted. None of the patients with or without G6PD deficiency showed symptoms, signs, or laboratory findings indicating hemolysis before administration of the drug and 4 days thereafter. In conclusion, tolfenamic acid is a strong antipyretic agent with excellent tolerance and high safety in children. Topics: Adolescent; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Child; Child, Preschool; Female; Fever; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Infant; Male; ortho-Aminobenzoates; Treatment Outcome | 1997 |
2 other study(ies) available for tolfenamic-acid and Fever
Article | Year |
---|---|
Pharmacology of tolfenamic acid.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Fever; Guinea Pigs; Humans; Inflammation; Male; Mice; ortho-Aminobenzoates; Pain; Prostaglandin Antagonists; Rabbits; Rats; Stomach Ulcer | 1994 |
Oral antipyretic therapy: evaluation of the N-aryl-anthranilic acid derivatives mefenamic acid, tolfenamic acid and flufenamic acid.
The antipyretic activity of three N-aryl-anthranilic acid derivatives, mefenamic acid, tolfenamic acid and flufenamic acid, was compared and their optimal antipyretic dose determined in a trial in 87 children (aged 5 months to 15 years), who suffered from infections and fever exceeding 38.5 degrees C. Tolfenamic acid proved to be the most potent antipyretic agent of the three drugs; it was eight times more powerful than mefenamic acid and three times more powerful than flufenamic acid. The optimal antipyretic doses were: mefenamic acid 4 mg/kg, tolfenamic acid 0.5 mg/kg and flufenamic acid 1.5 mg/kg. It is evident that the antipyretic activity of these anthranilic acid derivatives is even greater than their antirheumatic effect, the difference being most noticeable in the case of tolfenamic acid. Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Fever; Flufenamic Acid; Humans; Infant; Male; Mefenamic Acid; ortho-Aminobenzoates | 1978 |